Quest Diagnostics Incorporated (DGX)
| Previous Close | 135.64 |
| Open | 136.02 |
| Bid | 135.79 x 800 |
| Ask | 135.96 x 1100 |
| Day's Range | 135.41 - 136.51 |
| 52 Week Range | 119.59 - 145.58 |
| Volume | |
| Avg. Volume | 995,811 |
| Market Cap | 15.108B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 18.30 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (2.21%) |
| Ex-Dividend Date | Apr 05, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements With PathAI
Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, NJ and BOSTON, MA / ACCESSWIRE / May ...
- PR Newswire
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
- ACCESSWIRE
Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community
NORTHAMPTON, MA / ACCESSWIRE / May 2, 2024 / Quest Diagnostics: At a glance: Quest worked with St. James Health in Newark to provide no-cost Blueprint for Wellness® screenings during a Choose Healthy Life event to celebrate expansion of Newark, NJ-based ...
